Healthcare / Drug Manufacturers - Specialty & GenericToronto
$1.68
+0.01 (+0.60%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $3.2M · quality 41.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
68/100
B
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$166M
P/E
15.3x
↓EV/EBITDA
6.4x
↓ROE
12.8%
↑Gross Margin
43.9%
↓Debt/Equity
0.41
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+44.1%
FCF CAGR
—
FCF margin
12.7%
FCF / Net income
1.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $107.2M · net income $13.1M · FCF $13.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $107.2M | $107.2M | $81.7M | $57.3M | $35.8M |
| Net Income | $13.1M | $13.1M | $6.4M | $6.9M | $2.3M |
| EBITDA | $28.5M | $28.5M | $15.7M | $16.4M | $9.0M |
| EPS | 0.14 | 0.14 | 0.07 | 0.08 | 0.03 |
| Gross Margin | 43.9% | 43.9% | 36.4% | 47.6% | 48.4% |
| Operating Margin | 20.3% | 20.3% | 9.8% | 21.0% | 13.9% |
| Net Margin | 12.2% | 12.2% | 7.9% | 12.1% | 6.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.41 | 0.41 | 0.55 | 0.57 | 0.73 |
| Current Ratio | 3.06 | 3.06 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $13.7M | $13.7M | $3.2M | $-4.0M | $-21.5M |
| Returns | |||||
| ROE | 12.8% | 12.8% | 7.3% | 8.7% | 3.5% |
| Valuation | |||||
| P/E | 15.27 | 15.27 | 9.29 | 12.50 | 3.67 |
| EV/EBITDA | 6.39 | 6.39 | 6.45 | 7.99 | 5.10 |
| P/B | 1.52 | 1.52 | 0.68 | 1.13 | 0.14 |
| Growth & Yield | |||||
| Revenue Growth | 31.1% | 31.1% | 42.8% | 59.8% | — |
| EPS Growth | 100.0% | 100.0% | -12.5% | 166.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
2.1%
EPS terminal req.
$0.15
Spread vs growth
97.9%
5Y implied EPS CAGR
5.2%
EPS terminal req.
$0.18
Spread vs growth
94.8%
10Y implied EPS CAGR
7.6%
EPS terminal req.
$0.29
Spread vs growth
92.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+33.3%
Start / end P/E
18.0x → 12.0x
EPS bridge
0.07 → 0.14
Residual
-33.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.